News

Filter

1 to 9 of 17 results

FDA approves Baxter/Halozyme’s HyQvia

FDA approves Baxter/Halozyme’s HyQvia

14-09-2014

The US Food and Drug Administration on Friday approved Baxter International’s and Halozyme Therapeutics’…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

Positive top-line Ph III results for Baxter’s BAX 855 in hemophilia A

21-08-2014

US drugmaker Baxter International has announced positive results from its Phase III pivotal clinical…

AdvateBAX 855Baxter InternationalHematologyPharmaceuticalRegulationResearch

FDA advisory panel backs Baxter’s HyQvia for primary immunodeficiency

FDA advisory panel backs Baxter’s HyQvia for primary immunodeficiency

01-08-2014

The Blood Products Advisory Committee of the US Food and Drug Administration has voted 15-1 that HyQvia…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUS Food and Drug AdministrationUSA

FDA extends PDUFA date for Baxter and Halozyme’s HyQvia

21-05-2014

US drugmakers Baxter International and Halozyme Therapeutics revealed that the US Food and Drug Administration…

Baxter InternationalBiotechnologyHalozyme TherapeuticsHyQviaImmunologicalsRegulationUSA

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B

Baxter’s Feiba gains FDA approval for prophylactic treatment of hemophilia A and B

20-12-2013

US drugmaker Baxter International has received approval from the US Food and Drug Administration for…

Baxter InternationalFeibaHematologyPharmaceuticalRegulation

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

Baxter files amended BLA to FDA for HyQvia for primary immunodeficiency

02-12-2013

USA-based Baxter International has completed submission of an amended biologics license application to…

Baxter InternationalHalozyme TherapeuticsHyQviaImmunologicalsNorth AmericaPharmaceuticalRegulationUSA

FDA backs Baxter's Rixubis for hemophilia B; Breakthrough status for GSK's drisapersen

28-06-2013

The US Food and Drug Administration yesterday (June 27) approved Baxter International's (NYSE: BAX) Rixubis…

Baxter InternationaldrisapersenGlaxoSmithKlineNorth AmericaPharmaceuticalRare diseasesRegulationRixubis

1 to 9 of 17 results

COMPANY SPOTLIGHT

Menarini

Back to top